CD40 and neoplasm: Firstly, by enhancing the treatments themselves, for example Fc-engineering to potentiate macrophage-dependent effects of ICI; secondly, priming TAMs, through FcR engagement, CD40 agonism, or TLR stimulation, that can lead to alterations in the TME that will better promote immune responses and enhance the anti-tumor effects of current therapies.